The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients

The recently published ESC/EAS guidelines for the management of dyslipidaemias have lowered the low-density lipoprotein cholesterol (LDL-C) target in the very high risk patients below 55 mg/dL [1.4 mmol/L] [1]. The drug of choice for achieving this target is high-intensity statin to the highest tolerated dose. If the goal is not achieved, the addition of ezetimibe is recommended first, and then the addition of a proprotein convertase subtilisin/kexin type [9] inhibitor (PCSK9i), if LDL-C remains above target.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research